Cargando…
Targeting rare tumors: new focus for clinical research in China
Rare tumor has a huge unmet medical need without standard regimens, calling for novel therapeutic interventions. The National Cancer Center of China identified a threshold of incidence for rare tumor as 2.5/100,000, based on the characteristics of Chinese population. Molecular profiles for rare tumo...
Autores principales: | Wang, Shuhang, Jiang, Yale, Miao, Huilei, Fang, Yuan, Jiang, Ning, Yu, Yue, Ma, Peiwen, Tang, Qiyu, Cui, Dandan, Fang, Hong, Huang, Huiyao, Fan, Qi, Sun, Chao, Yu, Anqi, Miao, Shuangman, Du, Jingting, Zhu, Jingxiao, Wang, Yuning, Li, Ning |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9832829/ https://www.ncbi.nlm.nih.gov/pubmed/36437781 http://dx.doi.org/10.15252/emmm.202216415 |
Ejemplares similares
-
The reliability and integrity of overall survival data based on follow-up records only and potential solutions to the challenges
por: Huang, Huiyao, et al.
Publicado: (2022) -
Landscape and perspectives of macrophage -targeted cancer therapy in clinical trials
por: Wang, Shuhang, et al.
Publicado: (2022) -
Seven-year exclusivity and beyond for drugs of rare diseases in China
por: Jiang, Yale, et al.
Publicado: (2023) -
KRAS Mutation in Rare Tumors: A Landscape Analysis of 3453 Chinese Patients
por: Wang, Shuhang, et al.
Publicado: (2022) -
The global landscape of neoadjuvant and adjuvant anti-PD-1/PD-L1 clinical trials
por: Wu, Dawei, et al.
Publicado: (2022)